(1) Department of Medical Oncology, University General Hospital of Heraklion, Voutes, Heraklion, 71110 Crete, Greece;(2) Laboratory of Tumor Cell Biology, University of Crete, School of Medicine, Voutes, Heraklion, 71003, Crete, Greece
Abstract:
Background
The detection of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTC) before and/or after adjuvant chemotherapy in patients with operable breast cancer is associated with poor clinical outcome. Reliable prognostic markers for late disease relapse are not available. In this study we investigated the value of CTC detection during the first five years of follow-up in predicting late disease relapse.